Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON44175
NL-OMON44175
Completed
Not Applicable

Mindfulness Based Cognitive Therapy for bipolar disorder - MBCT for bipolar disorder

Radboudumc0 sites144 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBipolar disorderManic-Depressive disorder10026753

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bipolar disorder
Sponsor
Radboudumc
Enrollment
144
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
September 1, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Radboudumc

Eligibility Criteria

Inclusion Criteria

  • •\- bipolar I or II disorder
  • •\- having suffered at least two lifetime depressive episodes, either current or in (partial) remission at baseline (according to SCID assessment)
  • •\-having suffered at least one episode (depressed or (hypo)manic) within the year prior to baseline.
  • •\- Young Mania Rating Scale score \< 8

Exclusion Criteria

  • •\- a (hypo)manic episode in the 3 months before the start of the trial
  • •\- lifetime diagnosis of schizophrenia or schizoaffective disorder, current substance abuse disorder, organic brain syndrome, antisocial or borderline personality disorder
  • •\- risk of suicide or aggression
  • •\- the presence of a concurrent significant medical condition impeding the ability to participate

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Quality of life and benefit for patients: bipolar radiofrequency-induced thermotherapy (RFITT) versus crossectomy and strippingGreat saphenous vein insufficiencyCirculatory SystemVenous insufficiency (chronic) (peripheral)
ISRCTN11604626Artemed SE (Germany)200
Active, not recruiting
Phase 1
Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores
EUCTR2017-005059-10-BEGhent University Hospital180
Completed
Phase 2
Double-Blind Naltrexone in KleptomaniaKleptomania
NCT00332579University of Minnesota25
Active, not recruiting
Not Applicable
Efficacy of an organic pomegranate polyphenol complex (VIQUA®) in type 1 primary osteoporosis in post-menopausal womePrevention of osteoporosis in postmenopausal womenMusculoskeletal Diseases
ISRCTN13473651INNOVATION LABO Sciences Co., Ltd60
Active, not recruiting
Not Applicable
In this clinical study, a new drug, Budesonid 3 mg effervescent tablet for the preparation of a mouth rinse solution to treat oral chronic GvHD (Graft versus Host Disease) resulting from allogeneic (taken from different individuals of the same species) haematopoietic (blood cell forming) stem cell transplantation (HSCT), is evaluated.Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 16.0Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2008-004562-10-CZDr. Falk Pharma GmbH224